June is National Cancer Survivors Month and Uterine Cancer Awareness Month. When heavy vaginal bleeding sent Julie Herbert to a California emergency room in November 2024, cancer was the furthest thing from her mind. A triage nurse at the hospital was very concerned, and the 36-year-old research associate was quickly admitted. “They immediately put me into a room and gave me IV fluids and a blood transfusion,” Herbert said. A Pap test administered by the hospital came back abnormal. After follow-up testing, including a CT scan, an ultrasound and a biopsy, Herbert was diagnosed with advanced cervical cancer that had spread to her lymph nodes. “When they told me it was cancer, I was stunned,” she said. After all, seven days earlier, she had seen a gynecologist for abnormal bleeding. Herbert said the doctor had attributed this to heavy menstrual periods and the recent removal of her intrauterine device (IUD), and did not order any follow-up testing. Herbert — who’d been using an IUD for eight years — had had the device removed three months earlier. She’d experienced some bleeding on and off before it was removed, but it got worse after it was taken out. Bleeding can occur when an IUD is removed, but excessive, prolonged bleeding after a removal may indicate a more serious underlying medical condition. Given her history of bleeding and the intensity of it, Herbert believes the medical professionals that she saw should have done more. “They said this could just be my body getting back to normal after getting the IUD out and blamed it on my hormones,” Herbert said. Herbert’s experience is not uncommon. Ignoring abnormal bleeding can have serious consequences Abnormal vaginal bleeding — or abnormal uterine bleeding (AUB) when it originates in the uterus — affects up to 35% of women and is defined as bleeding that is unexpected or prolonged, including extremely heavy periods or irregular bleeding not related to menstruation. But despite its prevalence, and the fact that abnormal bleeding is a common symptom of gynecologiccal cancers, it is frequently overlooked or attributed to fibroids, hormones, irregular periods, birth control or cervical polyps — potentially leading to a missed diagnosis of a more serious problem. “Cancer can happen to anyone, and my bleeding was not taken as seriously as it should have been,” Herbert said. Medical gaslighting compounds the problem Medical gaslighting — when medical providers invalidate or dismiss patients’ questions, symptoms or concerns — is a significant issue in women’s health, particularly in cancer care. This can happen with all patients, but marginalized communities are often particularly affected. A study published in BMC Women’s Health found that women have “consistently reported poor experiences in accessing care” for abnormal uterine bleeding throughout the last 20 years. Elena Ratner, M.D., a gynecologic oncologist at Yale Cancer Center, said that she frequently has patients come to her after they have seen numerous other medical providers who did not address their unexpected bleeding. “Abnormal bleeding is a tangible, clear symptom that should not be ignored, yet women are not being listened to,” Ratner said. Abnormal bleeding can happen for many different reasons and is not always a sign of cancer, Ratner explained. “However, it is essential that patients are properly evaluated to determine the cause, particularly since early diagnosis is crucial for gynecological cancers,” she added. Women’s pain has been normalized Several recent studies have found a gender pain bias, where medical providers assume women are exaggerating their pain. Menstrual pain and bleeding are also frequently seen as an inevitable experience for women, which leads to symptoms not being taken as seriously — even though tumors on the uterus and ovaries can cause pressure and pain that are similar to menstrual cramps. Ami Vaidya, M.D., an oncologist and co-chief of the Division of Gynecologic Oncology at Hackensack Meridian John Theurer Cancer Center, said that the ongoing normalization of menstrual-related pain and bleeding can cause patients to delay seeking help and may lead healthcare providers (HCPs) to overlook symptoms of a critical medical issue. “There is a significant and well-documented misconception in medicine where abnormal bleeding is sometimes dismissed as a normal part of ‘being a woman,’ which can lead to missed or delayed diagnoses of serious conditions,” said Vaidya. Despite diagnostic challenges, experts emphasize there are specific symptoms to gynecologic cancers that patients should be aware of and speak with their provider about, including: Abnormal bleeding — Any bleeding that is unexpected or prolonged, including extremely heavy periods or irregular bleeding not related to menstruation. Abnormal bleeding can be a symptom of each of the six types of gynecologic cancers — cervical, ovarian, uterine, vaginal, vulvar and fallopian tube (which is rare). Postmenopausal bleeding — If a patient is postmenopausal, meaning that they have not had a period in 12 months — any bleeding or spotting should not be ignored. Changes in menstruation — Heavier and/or longer menstrual bleeding than usual Urinary changes — Difficult, frequent or painful urination Pain or bleeding during or after intercourse — Any discomfort or spotting related to sexual activity Swelling or bloating — Feeling swollen or bloated in the lower abdomen Digestive changes — Changes in appetite, indigestion, nausea and chronic constipation Vaidya said there are different diagnostic exams that patients can discuss with their HCP that may help determine the cause of abnormal bleeding, including: Pelvic exam and Pap/HPV tests Blood tests to check for anemia or hormonal issues Transvaginal ultrasound to identify structural problems Endometrial biopsy to examine the uterine lining for cancerous cells Hysteroscopy for a direct visual inspection of the uterus Vaidya recommends that patients keep a symptom journal to track any pain and/or bleeding and bring a list of questions to their medical appointments. “If you feel dismissed, ask pointed questions such as, ‘What specific tests can we run to rule out more serious conditions like cancer?’ If a requested test is denied, insist that the doctor document the refusal in your chart — a step that often prompts action,”

Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Global Fatty Liver Day, an annual public education and awareness campaign, is observed June 11, 2026. A plethora of new and emerging treatments may change the trajectory of care for fatty liver disease. When Jerry Rosenberg boarded a cruise to Bermuda in April 2017, he was not expecting to return to the U.S. in an air ambulance a few days later. He spent the rest of the month in an induced coma before receiving a liver transplant. Unaware he had metabolic dysfunction-associated steatotic liver disease, an acute episode of hepatitis A — brought about by eating contaminated food — left Rosenberg in critical condition. Jerry Rosenberg “When I was very young, I’d had the [HAV] vaccine, but it was an old vaccine that should have been redone,” Rosenberg told Healio. Rosenberg is not alone. An estimated 1.3 billion people worldwide live with MASLD, according to a global health study in The Lancet Gastroenterology & Hepatology. The road to recovery was not easy. Rosenberg went through transplant rejection twice within 2 years and was prescribed heavy doses of steroids. During this period, Rosenberg became concerned with his weight gain and increased appetite. He reached out to Andrew P. Keaveny, MD, his transplant hepatologist at Mayo Clinic. “Weight gain is very common posttransplant,” Keaveny said. “Patients can experience recurrent fatty liver or develop fatty liver in their new liver.” Initially, Keaveny recommended Rosenberg start taking Mounjaro (tirzepatide, Eli Lilly & Co.), a dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist prescribed off-label for weight loss, but it was not covered by Rosenberg’s insurance. Instead, he began Ozempic (semaglutide, Novo Nordisk), which was. “When I had my once-a-year major checkup on the 9th anniversary of my liver transplant, I was given the news that after 3 years on Ozempic and trying to eat better, I have 0% fat on my liver,” Rosenberg said. Keaveny told Healio that while the dangers of fatty liver disease were appreciated from a hepatology perspective, there were not many treatment options available until recently. “That’s why it’s important to get the message out to [clinicians] to assess patients for fatty liver disease,” Keaveny said. “Previously the pushback was, what can you do about it? Everybody tries to lose weight and they’re not successful. But I think we’ve had a sea change in our approach to identifying and managing MASLD.” Rosenberg is now an advocate for organ donation and patients with fatty liver disease. Healio spoke with Rosenberg and Keaveny in recognition of Global Fatty Liver Day, an awareness campaign recognized annually on the second Thursday of June. Future of care There is an increasing burden of fatty liver disease among younger patients, especially younger males, Keaveny said, citing recent research. It will be important to determine the predominant factors contributing to the condition in this population and others, according to Keaveny. “We need to do more studies to better understand what the dominant player is from an epidemiologic point of view,” Keaveny said. “What are the interactions between disordered metabolism and alcohol.” Emerging therapies, like fibroblast growth factor 21 (FGF-21) analogues, may help alleviate the burden of fatty liver disease by regulating key metabolic pathways to reverse liver fibrosis. Several FGF-21 analogues are now in phase 3 study, including efimosfermin (GSK). “These are very promising as antifibrotic medications, even in patients who have very advanced disease,” Keaveny said. “Currently the treatments that are approved, both resmetirom (Rezdiffra, Madrigal Pharmaceuticals) and Wegovy (semaglutide, Novo Nordisk), are approved for patients who have moderate to severe disease, but not established cirrhosis.” “In the future, there will be multiple medications available, so figuring out sequential therapy and combination therapy is going to be very important, but I think we’re going to have compounds able to address the underlying fibrotic process,” he added. Keaveny also highlighted the significance of preventative medicine in tackling fatty liver disease, especially in light of Rosenberg’s case. “I recommend vaccination against HAV and hepatitis B to all my patients with any form of fatty liver disease, but HAV especially, because that’s one you can just pick up from contaminated food,” Keaveny said. Keaveny is optimistic that these new treatments will reduce the need for liver transplant. “Success in hepatology is reducing the number of patients who need liver transplantations, because if you look at the status of the epidemiology, we’re not going to be able to meet the demand for organs for patients with complications from this condition,” he said. A message for clinicians Screening patients for fatty liver disease — particularly those with type 2 diabetes or a family history of liver disease — is crucial, according to Keaveny. When a patient is diagnosed with fatty liver disease, it is also important to address comorbidities that may be present, he emphasized. “Mild fatty liver disease is a marker of metabolic stress, so it’s very important that individuals with the condition be counseled about their blood pressure, blood sugar and weight as well, to address cardiovascular risk factors,” Keaveny said. Clinicians can connect patients with internet resources to learn more about lifestyle interventions to address fatty liver disease. Keaveny recommends online patient education materials from the American Diabetic Association, American Liver Foundation and Mayo Clinic. He also recommends that clinicians connect patients with dietitians. “Behaviors change gradually, and ongoing support, encouragement and feedback are critical,” Keaveny said. Rosenberg highlighted the “beauty” of support groups for patients. After his transplant, Rosenberg became a member of Mayo Clinic’s Second Chance support group for individuals who have had liver, kidney or pancreas transplantation. “Those of us that have had successful

I’m standing in front of the mirror squeezing myself into pants that no longer button. I turn to the side and notice soft, squishy love handles, a new belly pooch and skinny legs. Who is this person staring back at me? I go to the gym at least three times a week, I stick to a mostly Mediterranean diet, and I walk everywhere. Why was I suddenly packing on the pounds? And where did these chicken legs come from? As a middle-aged woman in menopause, I knew wrinkles were inevitable. I was prepared for the brain fog and hot flashes, but the weight gain around my abdomen? No one had warned me. I tried to muster up some self-confidence about my body, but I couldn’t find any. Maybe it was hiding underneath all that new belly fat. I did what any other Gen X woman would do and turned to the internet for answers. On TikTok, one chiropractor blamed miscarriages for belly fat, a fitness guru suggested doing endless crunches on Instagram. A doctor on FB swore magnesium was the answer to my woes. Soon my feeds were inundated with ads for supplements and hacks. There was so much conflicting information, I didn’t know who or what to believe. So I signed off of social media and looked into scientific studies. I found out that gaining visceral fat in menopause is pretty common. According to the SWAN study, the majority of women in midlife gain between 4 and 5 pounds over a three-year period. Curious to find out more, I reached out to the experts to learn why this happens and what, if anything, I could do to slow my belly roll. Where does menopause belly fat come from? “Menopause belly is driven by estrogen decline and rising follicle-stimulating hormone (FSH),” said Sara Szal M.D., OB-GYN and author of Women, Food, and Hormones. When your estrogen drops during menopause, you begin to lose muscle mass and gain fat. This creates subcutaneous fat — the soft jiggly muffin top just below your skin. It also creates visceral fat — deeper fat that surrounds your internal organs including the liver, stomach and intestines. Along with drops in estrogen, high levels of FSH — a reproductive hormone — increase fat storage and slow metabolism. This makes it much more difficult to lose weight in midlife. As estrogen continues to drop, your fat gets redistributed from other parts of your body and settles in your belly. A meta-analysis of over 1 million women found that waist circumference increased by 4.6 cm and trunk fat rose by 5.5%, while leg fat significantly decreased by 3.2%. “That’s why the legs look thinner as the midsection grows,” said Salz. This explained my chicken legs. But that’s only part of the story. According to menopause expert Mary Claire Haver, M.D., when you don’t get enough sleep during menopause (and who is?), ghrelin, your hunger hormone, increases. Declining estrogen also reduces leptin, the hormone that tells you when you’re full. So not only are you hungrier, but your body doesn’t signal when you’ve eaten enough. Stress is another culprit. Salz said that chronic stress elevates the stress hormone cortisol, which contributes to visceral fat, insulin resistance and metabolic syndrome. When you’re stressed, you’re also more likely to make poor meal choices or snack on sugary foods. This all leads to inflammation in your body. Inflammation contributes to even more belly fat, brain fog and muscle pain. And this is not simply a vanity concern. It’s not just that we gain a few pounds or go up a few pant sizes. “Visceral fat is dangerous fat,” said Salz. It can increase the risk of breast cancer, dementia, diabetes, heart disease and even sudden death. How to get rid of menopause belly Luckily, there are steps you can take to shrink your menopause belly. Forget the hacks you see online, and follow these well-researched guidelines from Salz and Haver. Follow a Mediterranean diet Why it works: A Mediterranean diet rich in fruits and vegetables, whole grains, nuts, fish and olive oil helps reduce weight and inflammation. Eat protein Why it works: Protein preserves muscle, improves bone density and helps satisfy your hunger. Aim for 30 grams of protein per meal. Add fiber to your diet Why it works: Fiber is the hidden super power for menopause belly. It improves insulin sensitivity, reduces inflammation and helps control your appetite. Aim for 25-40 grams per day from plant-based whole foods, including berries, beans, whole grain oats and legumes. Avoid sugar Why it works: Sugar causes inflammation and contributes to the storage of visceral fat. Aim for less than 25 grams of added sugar per day. Exercise Why it works: Salz said combining high-intensity interval training (HIIT) with resistance training is the most effective way to improve body composition in postmenopausal women. You need a minimum of 150 minutes per week of moderate-intensity aerobic activity and twice weekly muscle-strengthening activities. Lower stress Why it works: Reducing stress lowers your cortisol levels. Make sleep a priority, drink less alcohol–it can spike your cortisol and mess with your sleep–, and consider cognitive behavioral therapy. Journaling, meditation, yoga and breathing exercises can also help. Look into hormone therapy Why it works: Hormone therapy (HT) increases estrogen levels in your body, which helps redistribute visceral belly fat. HT also can improve vasomotor symptoms of menopause (hot flashes and night sweats), sleep quality and your mood, all of which might help you have more energy to exercise consistently. Debunking the myths Now that we know what causes menopause belly, and what we can do about it, let’s hear what Salz said about these menopause belly myths. Myth 1: Crunches and ab workouts reduce belly fat. You cannot spot reduce. No amount of abdominal work will burn fat. Myth 2: Eat less, cardio more and your belly will come off. Aggressive caloric restriction in midlife strips lean mass and worsens the underlying problem. Myth 3: Hormone therapy makes you

Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Individuals who drank one sugar-sweetened beverage per day had increased risk for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Artificially sweetened beverages did not increase risk. Consuming sugar-sweetened beverages may significantly increase the risk for specific types of liver cancer. A pooled analysis including more than a million individuals found those who drank one sugar-sweetened beverage per day had a 10% greater risk for hepatocellular carcinoma and 15% greater risk for intrahepatic cholangiocarcinoma (ICC). Data derived from Watling CZ, et al. JAMA Netw Open. 2026;doi:10.1001/jamanetworkopen.2026.17754. Artificially sweetened beverages did not significantly increase the risk for any form of liver cancer. “The overall evidence for an association in humans between artificially sweetened beverages and liver cancer, and more specifically aspartame and HCC, is not strongly supported by these analyses,” Cody Z. Watling, DPhil, postdoctoral fellow in the division of cancer epidemiology and genetics at NCI, and colleagues wrote. “Based on this study and prior research associating sugar-sweetened beverages with adverse outcomes, individuals may benefit from reducing their intake of sugar-sweetened beverages.” Unknown risk factor? Global liver cancer diagnoses are projected to increase 55% by 2040, according to study background. In the U.S., more than 42,000 individuals are expected to be diagnosed in 2026, and nearly 31,000 will die from the disease, according to American Cancer Society’s Cancer Statistics 2026 report. Common risk factors for HCC, the most diagnosed form of the disease, include chronic hepatitis B or C virus infection, excessive alcohol use, smoking, metabolic dysfunction-associated steatotic liver disease (MASLD), obesity and diabetes. “However, an estimated 35% of HCC cases are not explained by known risk factors,” researchers wrote. Prior studies have produced mixed results on the potential association between aspartame, an artificial sweetener, and liver cancer. Previous research has associated sugar-sweetened beverages with multiple risk factors for liver cancer, including diabetes, MASLD and weight gain, but prospective studies have been limited in investigating the link to the malignancy itself. “We aimed to investigate associations between intake of artificially sweetened beverages and sugar-sweetened beverages and risk of total liver cancer, HCC and ICC,” researchers wrote. The pooled analysis of 11 prospective cohort studies included 1,518,411 participants (mean age, 57.8 years; standard deviation, 10.1; 58.2% women; mean BMI, 26.5 kg/m2, standard deviation, 5) who had no history of cancer. Enrollment across cohorts stretched from 1980 to 2009, and the overall study population had a median follow-up of 17.8 years. Participants self-reported intake of artificially sweetened and sugar-sweetened beverages. Incident liver cancer, HCC and ICC served as the primary endpoint. ‘The largest study’ Researchers did not observe a significant association with artificially sweetened beverages and liver cancer, HCC or ICC. “In models not adjusted for diabetes or BMI, we observed positive associations between artificially sweetened beverage consumption and liver cancer risk, but after adjustment for these confounders was made, outcomes were attenuated and there were no longer associations,” researchers wrote. “In most cohorts, participants who consumed one or more artificially sweetened beverages per day were more likely to have been diagnosed with diabetes and have a higher BMI at baseline than individuals who never or rarely consumed artificially sweetened beverages.” Watling and colleagues did find sugar-sweetened beverages had a significant association with both HCC (HR per 1 drink/day intake = 1.1; 95% CI, 1.03-1.18) and ICC (HR per 1 beverage/day intake = 1.15; 95% CI, 1-1.32), but not overall liver cancer. Individuals with baseline diabetes had similar risks for liver cancer regardless of their consumption of artificially sweetened and sugar-sweetened beverages. “It remains unclear whether increased consumption of sugar-sweetened beverages contributes to increased risk of HCC independent of obesity and diabetes,” researchers wrote. Watling and colleagues acknowledged study limitations, including self-reported consumption of artificially sweetened and sugar-sweetened beverages, and inability to stratify for underlying liver disease, including MASLD. “To our knowledge, this is the largest study to date to assess the association of artificially sweetened beverage and sugar-sweetened beverage intake with liver cancer risk,” they wrote. Perspective Back to Top The results were not particularly surprising, striking or unexpected, though they were drawn from a very thorough pooled analysis of studies with extended follow-up. This pooled analysis confirmed a very mild increased risk for liver cancer associated with sugar-sweetened beverages, but it did not demonstrate a significantly increased or reduced risk for liver cancer associated with the consumption of artificially sweetened beverages. It is difficult to determine if the risk associated with sugar-sweetened beverages is truly causal in nature or not. Given that these beverages have little to no nutritional value beyond the sugar itself, it may be wise to limit consumption. Importantly, the risks are not nearly as striking as those of other well-established risk factors for liver cancer, including liver cirrhosis or chronic infection with viral hepatitis B or C. Vaccination for hepatitis B, screening/treatment of hepatitis C, and avoiding exposure to known liver toxins, such as alcohol or aflatoxins, remain the bedrock recommendations for liver cancer prevention. It will be important to continue to investigate the possible associations between consumption of these beverages and other cancers or health hazards. Ernest Hawk, MD, MPH The University of Texas MD Anderson Cancer Center Disclosures: Hawk reports no relevant financial disclosures. Published by: Sources/Disclosures Source: Watling CZ, et al. JAMA Netw Open. 2026;doi:10.1001/jamanetworkopen.2026.17754. Reference: Disclosures: Watling reports no relevant financial disclosures. Please see the study for all other authors’ relevant financial disclosures. Ask a clinical question and tap into Healio AI’s knowledge base. PubMed, enrolling/recruiting trials, guidelines Clinical Guidance, Healio CME, FDA news Healio’s exclusive daily news coverage of clinical data Learn more

English El virus respiratorio sincitial (VRS) es una infección frecuente que ataca los pulmones y el sistema respiratorio. Es tan frecuente que muchos niños se infectan con el virus antes de su segundo cumpleaños. Pero el VRS no solo enferma a los niños, este virus también puede infectar a adultos. El VRS afecta la mucosa de las vías respiratorias y cuando el sistema inmunitario lanza un ataque, eso causa inflamación y una producción excesiva de mucosidad. Las vías respiratorias se estrechan y se obstruyen con mucosidad, residuos celulares y líquidos, lo que puede dar la sensación de soplar por un sorbete de plástico o de silbar por un acordeón desinflado cuando se trata de respirar. Si bien muchas infecciones son leves, bebés de menos de 2 meses, todos los adultos de más de 75 años y adultos de más de 50 años con trastornos crónicos tienen un mayor riesgo de infecciones graves y hospitalizaciones. ¿Cómo se disemina el VRS? El VRS es contagioso y se propaga como la gripe. Tos y estornudos expulsan microgotas diminutas al aire y a superficies. Puedes contagiarte del virus si respiras estas microgotas o si llegan a tus ojos, nariz o boca porque alguien tose o estornuda cerca de ti o si tocas una superficie contaminada y luego tocas tu rostro antes de lavar tus manos. Lee: ¿Es covid, el VRS o gripe? >> ¿Quién debería vacunarse en contra del VRS? En EE.UU., los Centros para el control y prevención de enfermedades (CDC, por sus siglas en inglés) recomiendan una vacuna contra el VRS para adultos de 75 años o más o para adultos de más de 50 años con trastornos que les dan un mayor riesgo de enfermarse gravemente con VRS y de hospitalizaciones. ¿Qué trastornos incrementan el riesgo de enfermarse gravemente con VRS? El VRS puede ser duro para personas con órganos deteriorados o con sistemas inmunitarios débiles. Algunos trastornos te dan un mayor riesgo de enfermarte gravemente con este virus. Estos trastornos son, entre otros: EPOC Insuficiencia cardiaca congestiva Diabetes Enfermedades hepáticas crónicas Obesidad Habla con tu proveedor de atención médica (HCP, por sus siglas en inglés) si no conoces con certeza tu riesgo. ¿Con qué frecuencia debes vacunarte contra el VRS? Actualmente, los CDC recomiendan solo una vacuna contra el VRS para adultos de más de 75 años o para adultos de 50 a 74 años que tienen mayor riesgo de enfermarse gravemente con el VRS. Deberías recibir esta vacuna incluso si la recibiste durante el embarazo. ¿Cuál es el mejor momento para vacunarse contra el VRS? La temporada del VRS generalmente es de octubre a marzo, aunque eso puede variar dependiendo de la parte del país en que vives. El mejor momento para vacunarse es durante los últimos meses del verano o durante los primeros meses del otoño antes de que empiece la temporada de VRS, pero puedes vacunarte en cualquier momento. Pregunta a tu proveedor de atención médica en qué momento te recomienda que te vacunes en tu área. ¿Cuáles son los efectos colaterales de la vacuna contra el VRS? Las vacunas contra el VRS tienen efectos colaterales parecidos a los de otras vacunas, los cuales usualmente son leves, y podrían ser, entre otros: Dolor en el lugar de la inyección Fatiga Fiebre Dolor de cabeza Náuseas Dolor articular o muscular ¿Cuáles son los beneficios de la vacuna contra el VRS? Los beneficios de vacunarse superan inmensamente los riesgos. Vacunarse contra el VRS es el mejor método para prevenir enfermedades graves y complicaciones tales como eventos cardiacos desencadenados por la inflamación causada por el virus. También reduce sustancialmente las tasas de hospitalización causadas por el VRS para adultos mayores. Y un estudio incluso indica que vacunarse contra el VRS puede reducir el riesgo de demencia en etapas posteriores de la vida. Los beneficios de vacunarse contra el VRS son similares para personas embarazadas, previniendo hospitalizaciones y enfermedades graves. También proporciona protección al feto cuando la vacuna se aplica entre la semana 32 y 36 del embarazo. La vacunación durante el embarazo ha demostrado una reducción del 68% de hospitalizaciones para recién nacidos que se contagian del VRS. Si una mujer no se vacuna durante el embarazo, su bebé puede recibir una inyección para bebés de anticuerpos contra el VRS de acción prolongada después del nacimiento para evitar hospitalizaciones y enfermedades graves. Además de los beneficios médicos, vacunarte puede ayudar a tu comunidad. Sí comunidades tienen buenos niveles de vacunación, los adultos pierden menos días de trabajo, los estudiantes pierden menos días de escuela y los hospitales tienen menos carga por brotes de enfermedades. Este recurso educativo se preparó con el apoyo de Moderna. From Your Site Articles Related Articles Around the Web Source link

Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: A U.S. district judge voided an H-1B visa fee instituted in the fall. The fee would negatively affect the U.S. physician workforce, labor groups said. A bill before Congress would exempt health care workers. A federal judge voided a policy instituted by presidential proclamation last fall that raised the application fee for new H-1B visas to $100,000. As Healio previously reported, the H-1B visa program allows employers to temporarily hire foreign workers in certain occupations that require specialized knowledge, including certain international medical graduates. Nearly 250,000 international medical graduates worked in the United States in 2023, making up 24.7% of the total U.S. physician workforce. The fee increase was predicted to have large and lasting negative effects on the U.S. physician workforce, according to the AMA and medical specialty groups. In summary judgment in California v. Mullin, the judge ruled the fee increase violated the Administrative Procedure Act by imposing a tax that can be authorized only by Congress. The suit was brought in the U.S. District Court for the District of Massachusetts, but because the ruling was based on federal law, it applies nationwide, according to Linda Gemind, an immigration attorney at Benesch in Cleveland. “Although it’s likely not the end of the matter, the ruling should take us back to pre-implementation of the $100,000 fee — for now,” Gemind told Healio. “At this point it should be the standard fee, which is generally $3,380 ($780 filing fee, $1,500 [American Competitiveness and Workforce Improvement Act] fee, $500 fraud fee, $600 asylum fee) for most petitions.” The AMA praised the ruling. “Today’s decision blocking the $100,000 visa fee is a victory for patients,” AMA President Bobby Mukkamala, MD, said in a press release. “At a time when communities across the country face physician shortages and growing barriers to care, we should be removing obstacles — not creating new ones — to attract talented physicians and other highly skilled professionals. International medical graduates play a vital role in caring for patients, particularly in underserved and rural areas.” The Trump administration will likely appeal the ruling in the U.S. Court of Appeals for the First Circuit or the U.S. Supreme Court, if it can establish jurisdiction, Gemind said. A judge could stay the decision until after the appeals process, but that has not happened so far. If the ruling ultimately stands, employers who have already paid the increased fee will likely seek refunds and those who chose not to apply for a visa because of the fee will also likely litigate, according to Gemind. In addition to legal challenges to the fee increase, a bipartisan group introduced a bill — H.R. 7961 — in the U.S. House of Representatives in March, which would exempt health care workers. For more information: Linda Gemind can be reached at lgemind@beneschlaw.com. Published by: Sources/Disclosures Source: Healio Interviews References: AAMC U.S. Physician Workforce Data Dashboard. https://www.aamc.org/data-reports/report/us-physician-workforce-data-dashboard. Accessed June 10, 2026. AMA applauds court decision blocking $100,000 visa fee for physicians. https://www.ama-assn.org/press-center/ama-press-releases/ama-applauds-court-decision-blocking-100000-visa-fee-physicians. Published June 8, 2026. Accessed June 9, 2026. H. R. 7961. https://www.congress.gov/119/bills/hr7961/BILLS-119hr7961ih.pdf. Published March 17, 2026. Accessed June 10, 2026. National Center for Health Workforce Analysis. Physician Workforce: Projections, 2023-2038. https://bhw.hrsa.gov/sites/default/files/bureau-health-workforce/data-research/physicians-projections-factsheet.pdf. Published December 2025. Accessed June 10, 2026. Memorandum and order on plaintiffs’ motion for summary judgment (doc. no. 86) and defendants’ cross-motion for summary judgment and motion to dismiss (doc. no. 92). https://storage.courtlistener.com/recap/gov.uscourts.mad.293201/gov.uscourts.mad.293201.106.0.pdf. Published June 8, 2026. Accessed June 9, 2026. Disclosures: Gemind reports no relevant financial disclosures. Ask a clinical question and tap into Healio AI’s knowledge base. PubMed, enrolling/recruiting trials, guidelines Clinical Guidance, Healio CME, FDA news Healio’s exclusive daily news coverage of clinical data Learn more Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Source link